Spiritual Domain Important in Palliative Care: A Case Study

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 2
Volume 8
Issue 2

CLEVELAND, Ohio-The importance of the spiritual domain in comprehensive patient care was emphasized during the care of Mrs. S, a 64-year-old woman with renal cell carcinoma with bone metastasis, Cathy Palcisco, LISW, said at a symposium on palliative medicine held at the Cleveland Clinic Foundation.

CLEVELAND, Ohio—The importance of the spiritual domain in comprehensive patient care was emphasized during the care of Mrs. S, a 64-year-old woman with renal cell carcinoma with bone metastasis, Cathy Palcisco, LISW, said at a symposium on palliative medicine held at the Cleveland Clinic Foundation.

This patient was being cared for at home, but she refused to enter hospice care. She felt that she did not need it, Ms. Palcisco said. At the same time, the nurses caring for Mrs. S felt frustrated because they were having difficulties connecting with her.

Ms. Palcisco, acting on the suggestion of the nursing staff, paid a visit to the patient. When she was led to the patient’s bedroom, Mrs. S resisted meeting her, announcing instead, “I don’t need you. I’m not afraid to die. Who sent you here?”

Ms. Palcisco explained to Mrs. S that she worked as part of an interdisciplinary team at the Cleveland Clinic Center for Palliative Medicine. Her role was to listen to patients and family and help with any nonmedical needs. She then asked Mrs. S about the source of her strength.

Mrs. S immediately credited her family and God as the source of her strength. “My family helps,” she said. “God helped.” In the conversation that followed, Ms. Palcisco affirmed Mrs. S’s relationship with God and with her family. But she also gently asked about her use of the past tense in her statement “God helped.” Although defensive at first, Mrs. S reluctantly admitted that, in the early stages of her illness, God had answered her prayers for more time and continued independence. Lately, however, it seemed that her prayers had gone unanswered.

Again, very gently, Ms. Palcisco questioned Mrs. S about her prayers and hopes, and learned that it was not death Mrs. S. feared so much as abandoning the care of her family. She needed assurance that her adult children and her husband would be okay without her.

With Ms. Palcisco’s help, Mrs. S was able to affirm the positive growth she had seen recently in her son and daughter, and express confidence that these positive changes would remain. But she worried greatly about her husband, a man who couldn’t talk about his feelings.

Ms. Palcisco agreed with the patient that that aspect of Mr. S probably wasn’t going to change, but perhaps there was something Mrs. S could do. Perhaps Mrs. S could review with her husband their life together and give him some specific things to remember. Mrs. S agreed to do this. Three days later, she died.

The tears the family has shed have been “very healing,” Ms. Palcisco said. Mr. S has been able to talk about his feelings and go on with his life.

The hospice team credits Ms. Palcisco for this especially pivotal visit. She said that she “didn’t play chaplain” but that her counseling skills as a social worker allowed her to give Mrs. S the help she needed.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Related Content